Suppr超能文献

C-8位卤素和甲氧基部分增强氟喹诺酮活性:对耻垢分枝杆菌gyrase抗性突变体和金黄色葡萄球菌gyrase-拓扑异构酶IV双突变体的作用

Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

作者信息

Lu T, Zhao X, Li X, Drlica-Wagner A, Wang J Y, Domagala J, Drlica K

机构信息

Public Health Research Institute, 455 First Ave., New York, NY 10016, USA.

出版信息

Antimicrob Agents Chemother. 2001 Oct;45(10):2703-9. doi: 10.1128/AAC.45.10.2703-2709.2001.

Abstract

The increasing prevalence of antibiotic resistance among bacterial pathogens prompted a microbiological study of fluoroquinolone structure-activity relationships with resistant mutants. Bacteriostatic and bactericidal activities for 12 fluoroquinolones were examined with a gyrase mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. For both organisms C-8 halogen and C-8 methoxy groups enhanced activity. The MIC at which 99% of the isolates tested were inhibited (MIC(99)) was reduced three- to fivefold for the M. smegmatis mutant and seven- to eightfold for the S. aureus mutant by C-8 bromine, chlorine, and methoxy groups. With both organisms a smaller reduction in the MIC(99) (two- to threefold) was associated with a C-8 fluorine moiety. In most comparisons with M. smegmatis the response to a C-8 substituent was similar (within twofold) for wild-type and mutant cells. In contrast, mutant S. aureus was affected more than the wild type by the addition of a C-8 substituent. C-8 halogen and methoxy groups also improved the ability to kill the two mutants and the respective wild-type cells when measured with various fluoroquinolone concentrations during an incubation period equivalent to four to five doubling times. Collectively these data help define a group of fluoroquinolones that can serve (i) as a base for structure refinement and (ii) as test compounds for slowing the development of fluoroquinolone resistance during infection of vertebrate hosts.

摘要

细菌病原体中抗生素耐药性的日益普遍促使人们对氟喹诺酮与耐药突变体的构效关系进行微生物学研究。用耻垢分枝杆菌的gyrase突变体和金黄色葡萄球菌的gyrase -拓扑异构酶IV双突变体检测了12种氟喹诺酮的抑菌和杀菌活性。对于这两种生物体,C - 8位卤素和C - 8位甲氧基增强了活性。C - 8位的溴、氯和甲氧基使耻垢分枝杆菌突变体的99%受试分离株被抑制时的最低抑菌浓度(MIC(99))降低了三到五倍,使金黄色葡萄球菌突变体的MIC(99)降低了七到八倍。对于这两种生物体,C - 8位氟部分使MIC(99)有较小程度的降低(两到三倍)。在与耻垢分枝杆菌的大多数比较中,野生型和突变体细胞对C - 8位取代基的反应相似(在两倍以内)。相比之下,添加C - 8位取代基时,金黄色葡萄球菌突变体比野生型受影响更大。在用相当于四到五个倍增时间的孵育期内的各种氟喹诺酮浓度测量时,C - 8位卤素和甲氧基也提高了杀死这两种突变体及各自野生型细胞的能力。总体而言,这些数据有助于确定一组氟喹诺酮,它们可(i)作为结构优化的基础,(ii)作为在脊椎动物宿主感染期间减缓氟喹诺酮耐药性发展的测试化合物。

相似文献

3
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.
4
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.
Antimicrob Agents Chemother. 2000 Dec;44(12):3337-43. doi: 10.1128/AAC.44.12.3337-3343.2000.
5
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. doi: 10.1128/AAC.45.12.3544-3547.2001.
8
Activity of and resistance to moxifloxacin in Staphylococcus aureus.
Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5. doi: 10.1128/AAC.47.4.1410-1415.2003.
9
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. doi: 10.1128/AAC.00158-07. Epub 2007 May 14.
10
Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Antimicrob Agents Chemother. 2002 Aug;46(8):2498-506. doi: 10.1128/AAC.46.8.2498-2506.2002.

引用本文的文献

1
Antimicrobial Susceptibility Patterns and Antimicrobial Therapy of Infections Caused by Species.
Medicina (Kaunas). 2024 Dec 2;60(12):1990. doi: 10.3390/medicina60121990.
3
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153.
4
Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.
Pharmaceutics. 2021 Aug 18;13(8):1289. doi: 10.3390/pharmaceutics13081289.
5
Molecular Characteristics and Antimicrobial Susceptibility Profiles of Clinical Isolates in Shanghai, China.
Infect Drug Resist. 2020 Jan 29;13:247-256. doi: 10.2147/IDR.S240963. eCollection 2020.
6
Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.
Infect Dis Ther. 2018 Jun;7(2):197-217. doi: 10.1007/s40121-018-0198-x. Epub 2018 Mar 31.
7
Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.01622-17. Print 2018 Mar.
10
How antibiotics kill bacteria: from targets to networks.
Nat Rev Microbiol. 2010 Jun;8(6):423-35. doi: 10.1038/nrmicro2333. Epub 2010 May 4.

本文引用的文献

1
Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
Antimicrob Agents Chemother. 2001 Jul;45(7):1994-2000. doi: 10.1128/AAC.45.7.1994-2000.2001.
2
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.
Antimicrob Agents Chemother. 2000 Dec;44(12):3344-50. doi: 10.1128/AAC.44.12.3344-3350.2000.
3
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.
Antimicrob Agents Chemother. 2000 Dec;44(12):3337-43. doi: 10.1128/AAC.44.12.3337-3343.2000.
4
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.
J Infect Dis. 2000 Aug;182(2):517-25. doi: 10.1086/315708. Epub 2000 Jul 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验